IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Keith BIGGADIKE et al.

Serial No.: To be assigned

Filing Date: Concurrently herewith

Art Unit: To be assigned

Examiner: To be assigned

For: Specific Glucocorticosteroid Compounds

Having Anti-Inflammatory Activity

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

		nts request that the references identified on Form PTO-1449 appended hereto be considered by the er and officially made of record in accordance with the provisions of 37 CFR 1.97
	įį	Copies of the references are enclosed Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) A copy of the International Search Report which issued on International Application No. PCT/EP2004/007819 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	OR []	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
B.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 or an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

10/564325 IAP15 Rec'd PCT/PTO 11 JAN 2006

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under §
		1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the
		issue fee. Also enclosed is a copy of the International Search Report which Issued on International
		Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

James R. Riek
Attorney of Record

Registration No. 39,009

Date: <u>January 11, 2006</u>

GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8022 Facsimile: (919) 483-7988

10/564325AP15 Rec'd PCT/PTO 11 JAN 2006

FORM PTO			-		SERIAL NO. FILING DATE APPLICANT GROUP		To be as	To be assigned Concurrently herewith	
INFORMA	TION	DISCLOSURE ST	FATEMENT						
							Keith Bi	ggadike et al.	
							To be as		
					EXAMINER		To be as		
					ATTORNEY	DOCKET NO.		PB60390USw	
			U.S.	PATENT D	OCUMENTS				
	T			}				Filing Date	
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	If Appropriate	
	1.	3,856,828	12/24/1974	PHILLIP	PS et al.			1	
	1							† · · · · · · · · · · · · · · · · · · ·	
	1							 	
	1			1					
	1								
	1			 					
	1			1			-1."		
	· · · · ·			Continue on	page			<u> </u>	
· · · · · ·					T DOCUMENT	'S	_		
	T	Document	Publication	1				Translation	
		Number	Date	1 .	Country	Class	Subclass	Yes No	
-	2.	GB 1384372	02/19/1975	GB					
	3.	GB 1514476	06/14/1978	GB				1	
	4.	GB 2079755	01/27/1982	GB				1	
	5.	GB 2137206	10/03/1984	GB					
	6.	WO 89/03390	04/20/1989	PCT					
	7.	WO 02/00679	01/03/2002	PCT					
				1					
	1			1					
				1				†	
				1		-		1	
			(Continue on	page				
		OTHER DOCU				Date, Page Num	ber, Etc.)		
1	8.	Ueno et al., "Synth	esis and evaluati	on of anti-in	flammatory activ	vities of a series	of corticostero	oid 17.alpha	
		esters containing a	functional group	," Journal o	f Medicinal Cher	mistry 34(8):246	8-2473 (Aug.	1991).	
			-						
		- -			 -				
			•						
			•						
		_							
				Continue on	page				
EXAMINE	R					DATE	CONSIDERE	.D	
		 							
±XAMINEI	K: Init	tial if citation consid	ered, whether or	not citation	is in conformance	e with MPEP §	609; Draw lin	e through	
citation if no	ot in co	onformance and not	considered. Incl	ude copy of	this form with no	ext communicati	on to the appl	icant.	